Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Till

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
American Journal of Hematology|January 22, 2019
Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCLStephen D Smith, Prathima Reddy, Alexandra Sokolova, et al.
Cancer Immunology Research|May 20, 2016
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of RituximabGregory A Rufener, Oliver W Press, Philip Olsen, et al.
Blood Advances|June 17, 2025
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomasChristina Poh, Jenna M Voutsinas, Mazyar Shadman, et al.
Cancer Research|June 2, 2017
Venetoclax Synergizes with Radiotherapy for Treatment of B-cell LymphomasShyril O'Steen, Damian J Green, Ajay K Gopal, et al.
British Journal of Haematology|February 8, 2020
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapyStephen D Smith, Brian G Till, Mazyar S Shadman, et al.
Journal of Cellular and Molecular Medicine|December 1, 2022
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world studyLorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantationLihua E Budde, Katherine A Guthrie, Brian G Till, et al.
Frontiers in Immunology|August 1, 2022
Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced MalignanciesHao Huang, Ling Peng, Bicheng Zhang, et al.
Leukemia & Lymphoma|July 11, 2022
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphomaLorena Panaite, Qian Vicky Wu, Jenna Voutsinas, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 5, 2023
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-UpCarrie Ho, Ajay K Gopal, Brian G Till, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
American Journal of Hematology|January 22, 2019
Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCLStephen D Smith, Prathima Reddy, Alexandra Sokolova, et al.
Cancer Immunology Research|May 20, 2016
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of RituximabGregory A Rufener, Oliver W Press, Philip Olsen, et al.
Blood Advances|June 17, 2025
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomasChristina Poh, Jenna M Voutsinas, Mazyar Shadman, et al.
Cancer Research|June 2, 2017
Venetoclax Synergizes with Radiotherapy for Treatment of B-cell LymphomasShyril O'Steen, Damian J Green, Ajay K Gopal, et al.
British Journal of Haematology|February 8, 2020
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapyStephen D Smith, Brian G Till, Mazyar S Shadman, et al.
Journal of Cellular and Molecular Medicine|December 1, 2022
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world studyLorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantationLihua E Budde, Katherine A Guthrie, Brian G Till, et al.
Frontiers in Immunology|August 1, 2022
Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced MalignanciesHao Huang, Ling Peng, Bicheng Zhang, et al.
Leukemia & Lymphoma|July 11, 2022
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphomaLorena Panaite, Qian Vicky Wu, Jenna Voutsinas, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 5, 2023
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-UpCarrie Ho, Ajay K Gopal, Brian G Till, et al.
Pageof 12